Program
YJ001
A development code. Also written as “YJ001 for Spray Use”, “YJ001 Spray 240 mg/day” and “YJ001 Spray 480 mg/day”.
Its studies are mostly in Neuralgia · Diabetes Mellitus, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Zhejiang Hanmai Pharmaceutical Technology | 22 open or running | phase 3since Sep 20, 2026 | Mar 19, 2024 | Aug 30, 2028phase 3 · NCT07859111 |
| Yuejia Pharmaceuticals (USA) | 10 open or running | phase 1since Jun 28, 2022 | Jun 28, 2022 | none ahead |
| Zhejiang Yuejia Pharmaceuticals | 10 open or running | phase 2since Sep 20, 2026 | Sep 20, 2026 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 28, 2022First study: phase 1 study in Safety and TolerabilityNew to Yuejia Pharmaceuticals (USA)Yuejia Pharmaceuticals (USA) · NCT05451667 · 32 enrolled · United States
- Mar 19, 2024Zhejiang Hanmai Pharmaceutical Technology's first study: phase 1 study in Diabetes MellitusNew to Zhejiang Hanmai Pharmaceutical TechnologyZhejiang Hanmai Pharmaceutical Technology · NCT06361108 · 24 planned · United States
- Sep 20, 2026Phase 3 study in Diabetic Peripheral Neuropathic Pain (DPNP)Phase 3 reachedZhejiang Hanmai Pharmaceutical Technology · NCT07859111 · 400 planned · China
- Sep 20, 2026Zhejiang Yuejia Pharmaceuticals's first study: phase 2 study in Diabetic Peripheral Neuropathic Pain (DPNP)New to Zhejiang Yuejia PharmaceuticalsZhejiang Yuejia Pharmaceuticals · NCT07858344 · 196 enrolled · China
Ahead
- Aug 30, 2028Primary completion: phase 3 study in Diabetic Peripheral Neuropathic Pain (DPNP)Zhejiang Hanmai Pharmaceutical Technology · NCT07859111
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07859111Diabetic Peripheral Neuropathic Pain (DPNP) · China | 3 | Recruiting | Zhejiang Hanmai Pharmaceutical Technology | Aug 30, 2028 | 400 |
| NCT07858344Diabetic Peripheral Neuropathic Pain (DPNP) · China | 2 | Completed | Zhejiang Yuejia Pharmaceuticals | Dec 27, 2024 | 196 |
| NCT06361108Diabetes Mellitus · United States | 1 | Recruiting | Zhejiang Hanmai Pharmaceutical Technology | Dec 20, 2025 | 24 |
| NCT05451667Safety and Tolerability · United States | 1 | Completed | Yuejia Pharmaceuticals (USA) | Dec 20, 2022 | 32 |
How it is read
Names in the registry
- “YJ001 for Spray Use”, 2 entries
- “YJ001 Spray 240 mg/day”, 1 entry
- “YJ001 Spray 480 mg/day”, 1 entry
- “YJ001 Spray 960 mg/day”, 1 entry
- “YJ001 spray”, 1 entry
Codes read as this program: YJ001.
Conditions, from the studies’ own filings
- Neuralgia, 2 studies
- Diabetes Mellitus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.